Topics

Glioblastoma | Treatment | Targeted therapy | Bevacizumab | Irinotecan

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Bevacizumab > Irinotecan

Akbas S, Alan O, Yildiz O, Karakurt M, Yildirim EC, Colak R, Yilmaz M, Celebi A, Er O, Celayir OM, Akdag MO, Sacli O, Ozcelik M, Sahin E, Ozdemir M, Dogu GG, Demir A, Gunaltili M, Elcicek OF, Sakalar T, Karabuga B, Yildiz F, Cavdar E, Ozkan O, Ozturk AE, Akagunduz B, Kuvvet BB, Selcukbiricik F.
Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study.
J Neurooncol. 2026 Jan 5;176(2):152. doi: 10.1007/s11060-025-05415-0. PMID: 41492105. Observational study˰ ˍ